alexa Outcomes Of Newly Diagnosed Diffuse Large B Cell Lymphoma Treated With Rituximab Dose-adjusted EPOCH And Rituximab-CHOP At King Chulalongkorn Memorial Hospital
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th World Hematologists Congress
May 08-09, 2017 Barcelona, Spain

Tanintorn Sinsomboonthong and Kitsada Wudhikarn
Chulalongkorn University, Thailand
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-023
Abstract
Background: Since the introduction of rituximab (R), outcome of diffuse large B cell lymphoma (DLBCL) has significantly improved. R-CHOP (C: Cyclophosphamide, H: Adriamycin, O: Vincristine and P: Prednisolone) has been the standard treatment over the past decade. However, about 30% of DLBCL relapsed or were refractory to the treatment. There were evidence showing benefit of adding etoposide (E) and administrating treatment in a dynamic dose adjusting fashion so called dose-adjusted (DA) EPOCH. Several phase II trials showed promising outcome of R-DA-EPOCH especially in some DLBCL subtypes such as primary mediastinal B cell lymphoma. We hypothesized that R-DA-EPOCH would be better than R-CHOP in DLBCL not otherwise specified (NOS). Herein, we compared treatment outcome of DLBCL patients treated with R-CHOP and R-DAEPOCH at our institution. Samples & Methods: We identified 178 newly diagnosed DLBCL-NOS patients treated with at least one cycle of R-CHOP or R-DA-EPOCH at the King Chulalongkorn Memorial Hospital between January 2011 and August 2016 (150 R-CHOP and 28 R-DA-EPOCH). We described baseline characteristics, treatment and compared toxicities including outcomes between R-CHOP and R-DA-EPOCH treated DLBCL patients. Results: Baseline characteristics are summarized in table 1. R-DA-EPOCH treated patients were significantly older, had higher proportion of B symptoms, elevated LDH and high intermediate/high risk diseases. The overall response rate was similar between two groups (97.3% in R- CHOP vs. 92.9% in R-DA-EPOCH). At the time of analysis, 20 patients had died (15 R-CHOP and R-DA-EPOCH). With a median follow up duration of 32 months, 2-year progression free survival (PFS), overall survival (OS) for the entire cohort was 89% and 92.1% respectively. R-CHOP treated patients had similar PFS but marginally better OS than R-DA-EPOCH cohorts (90.2% vs. 80.9%, P=0.09 for PFS and 93.1% vs. 85.3%, P=0.05 for OS) (Figure 1). Subgroup analysis on 77 high-risk patients, PFS and OS were not different between R-CHOP and R-DA-EPOCH treated patients (Figure 2). R-DA-EPOCH had more grade III/IV hematological toxicities. Univariable analysis identified elevated LDH, advanced stage disease and HI/high IPI as significant risk factor of inferior survival. Cell of origin was not a predictive factor in our cohort but germinal center B cell (GCB) like DLBCL who received R-DA-EPOCH showed trend toward better survival. Using multiple variable cox proportional hazard analysis, HI/high IPI is the only independent factor of inferior survival. Conclusions: In our study, DLBCL treated with R-DA-EPOCH had similar outcome to R-CHOP treated cohort. Whether R-DA-EPOCH would be more beneficial for specific subset, this finding may be re-evaluated in larger prospective controlled trial. Further analysis of CALGB 50303 is pending and would be informative.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords